Merck & Co., Inc. (MRK) Stock Analysis
Last updated Oct 27, 2026
Published Opportunity Closed
Position closed on Aug 19, 2026 at $152.20 — Target reached . Return and QQQ are frozen from the exit date.
Health Check
Last analyzed Oct 23, 2026
- Financial Health 65
- Profitability 40
- Business Quality 80
- Balance Sheet 55
- Cash Flow 70
Why this rating?
Health 62/100 — Good Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Merck & Co., Inc. (MRK) is a Drug Manufacturers - General company in the Healthcare sector. Compound Radar rates Merck & Co., Inc. 62/100 (Good Quality) due to high business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Moderate
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 112.56
- Forward P/E 15.36
- PEG 2.65
- EV/Revenue 5.92
Profitability
- Revenue Growth 5.1%
- Gross Margin 75.9%
- Operating Margin -0.2%
- Net Margin 4.8%
- ROE 7.0%
Financial strength
- Cash $7.14B
- Debt $53.91B
- Net Cash $-46.77B
- Free Cash Flow $12.36B
- Current Ratio 1.32
Similar companies
Peers in Drug Manufacturers - General, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Eli Lilly and Company Drug Manufacturers - General LLY$1,281.91 86 Health 86 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- AstraZeneca PLC Drug Manufacturers - General AZN$170.08 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Gilead Sciences, Inc. Drug Manufacturers - General GILD$159.08 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Biogen Inc. Drug Manufacturers - General BIIB$252.73 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- AbbVie Inc. Drug Manufacturers - General ABBV$286.39 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Bristol-Myers Squibb Company Drug Manufacturers - General BMY$61.55 72 Health 72 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Pfizer Inc. Drug Manufacturers - General PFE$29.80 71 Health 71 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Johnson & Johnson Drug Manufacturers - General JNJ$268.73 69 Health 69 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
FAQ
How Compound Radar scores and tracks Merck & Co., Inc. (MRK).